lipopolymer + small interfering RNA

Lipopolymer + small interfering RNA refers to a therapeutic platform (colloquially known as LPNPs) consisting of a novel lipopolymer delivery vehicle—specifically low-molecular-weight polyethyleneimine (PEI, 1.2 kDa) conjugated with aliphatic lipids—complexed with small interfering RNA (siRNA). Developed by researchers at the University of Alberta and collaborating institutions, this platform is designed to overcome the delivery challenges associated with RNA interference in hematologic malignancies, such as rapid degradation and poor cellular uptake. The cationic nature of the PEI facilitates siRNA binding, while the lipid modification enhances uptake and improves biodistribution to leukemia-affected tissues like the bone marrow and spleen. Preclinical studies have demonstrated that LPNPs can effectively deliver siRNAs targeting aggressive fusion oncogenes, including KMT2A::AFF1, KMT2A::MLLT3, and BCR::ABL1, resulting in robust gene silencing, induction of apoptosis, and significantly improved survival in models of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

Other names

lipopolymer/siRNA nanoparticleslipopolymer-mediated siRNA delivery platform